Clinical trial
The Effects of Alendronate After Cure of Primary Hyperparathyroidism
NCT00359385 · Columbia University, Other · Withdrawn
Key facts
| NCT number | NCT00359385 |
|---|---|
| Title | The Effects of Alendronate After Cure of Primary Hyperparathyroidism |
| Official title | The Effects of Alendronate After Cure of Primary Hyperparathyroidism |
| Acronym | AlenPostPara |
| Lead sponsor | Columbia University, Other |
| Collaborators | Merck Sharp & Dohme LLC Industry |
| Status | Withdrawn |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hyperparathyroidism |
| Intervention type | Drug |
| Interventions | Alendronate 70mg weekly |
| Enrollment | 0 |
| Start date | Jul 1, 2006 |
| Primary completion | Sep 1, 2009 |
| Completion | Sep 1, 2009 |
| First posted | Aug 2, 2006 |
| Last update posted | Nov 16, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: